75,000 Shares in Contineum Therapeutics, Inc. $CTNM Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM bought a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the second quarter, Holdings Channel.com reports. The fund bought 75,000 shares of the company’s stock, valued at approximately $298,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CTNM. ADAR1 Capital Management LLC increased its holdings in shares of Contineum Therapeutics by 105.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 168,765 shares of the company’s stock worth $1,178,000 after buying an additional 86,531 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Contineum Therapeutics during the 2nd quarter worth $140,000. Dynamic Technology Lab Private Ltd purchased a new position in Contineum Therapeutics in the first quarter worth $118,000. Nuveen LLC bought a new position in Contineum Therapeutics in the first quarter valued at $93,000. Finally, Strs Ohio bought a new position in Contineum Therapeutics in the first quarter valued at $27,000.

Contineum Therapeutics Trading Down 0.7%

NASDAQ CTNM opened at $10.93 on Friday. The firm has a market cap of $306.50 million, a PE ratio of -4.86 and a beta of 1.26. Contineum Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $20.24. The stock has a 50-day moving average of $11.43 and a 200-day moving average of $7.32.

Contineum Therapeutics (NASDAQ:CTNM) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.13. As a group, equities research analysts forecast that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CTNM. Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners started coverage on Contineum Therapeutics in a report on Thursday, September 25th. They set an “outperform” rating and a $20.00 price objective on the stock. Morgan Stanley upped their target price on Contineum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. Leerink Partnrs upgraded shares of Contineum Therapeutics to a “strong-buy” rating in a research report on Thursday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.20.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).